



# Could the HALP score indicate poor prognosis in colorectal cancer patients?

Ömer Çağlıyan<sup>1</sup>, Hilmi Yazıcı<sup>2</sup>, Ahmet Can Yaşar<sup>3</sup>, Yaşar Çağlar Bekki<sup>3</sup>, Sedat Tan<sup>3</sup>, Erkan Oymacı<sup>3</sup>, Ahmet Mücteba Öztürk<sup>3</sup>, Mehmet Yıldırım<sup>3</sup>

<sup>1</sup>Department of Surgical Gastroenterology, University of Health Sciences Türkiye, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye

<sup>2</sup>Department of General Surgery, Marmara University, Pendik Training and Research Hospital, İstanbul, Türkiye

<sup>3</sup>Department of General Surgery, University of Health Sciences Türkiye, İzmir City Hospital, İzmir, Türkiye

## ABSTRACT

**Objective:** Colorectal cancer (CRC) is a major health problem worldwide. According to estimates for the year 2030, cancer will be the number one cause of death for both genders. CRC is the third most common type of cancer and the second most common cause of cancer-related deaths. Various parameters are needed to provide information about the course and prognosis of the disease.

**Material and Methods:** The study included 103 patients diagnosed with CRC between 2017 and 2023. The patients' HALP scores were retrospectively analyzed together with clinical data. The relationship between survival times, disease stage, and treatment response was examined.

**Results:** The obtained data showed that low HALP scores were associated with worse overall survival. Although the HALP score cut-off value was found to be different in various studies conducted on benign or malignant diseases, a low HALP score indicates a poor prognosis. In our study, a HALP score below 23 was found to be associated with low overall survival.

**Conclusion:** This study suggests that a low HALP score is associated with poor prognosis and could serve as a valuable prognostic marker in the clinical management of CRC patients. However, certain limitations must be considered. While albumin is a marker of systemic inflammation and nutritional status, its specificity is limited in acute and chronic inflammatory conditions, which may impact the prognostic value of the HALP score. Further investigation into the biological mechanisms underlying this relationship and the potential of the HALP score in predicting treatment response would enhance its clinical applicability.

**Keywords:** Colorectal cancer, HALP score, prognosis, survival

## INTRODUCTION

Cancer is a significant health problem worldwide. Estimates for 2030 predict that cancer will be the number one cause of death for both genders (1). Colorectal cancer (CRC) is the third most common type of cancer and the second most common cause of cancer-related deaths (2). The American Cancer Society predicts that approximately 153,020 people will be newly diagnosed with CRC in 2023 (2).

The most commonly used method for staging colon CRC is tumour, node, metastasis (TNM) staging. TNM staging is a scoring system that evaluates the invasion of the tumor into the colon layers, the number of metastases to the lymph nodes of the relevant colon segment, and whether there is metastasis to distant organs (3,4). The stage of the disease is still the most important prognostic factor for CRC. Nevertheless, recent research has focused on different prognostic factors for CRC.

It is well known that systemic inflammation and nutrition play a role in the proliferation of cancer cells, local invasion, and metastasis to lymph nodes or distant organs (5). Deficiencies in immunity and nutrition have been associated with cancer cells exhibiting aggressive behavior. In previous studies, blood cells such as platelets, monocytes, neutrophils, and lymphocytes have been associated with tumor proliferation, invasion, and distant organ metastasis, and have been found to be significant (6). Attempts have been made to obtain information about the course

**Cite this article as:** Çağlıyan Ö, Yazıcı H, Yaşar AC, Bekki YÇ, Tan S, Oymacı E, et al. Could the HALP score indicate poor prognosis in colorectal cancer patients? *Turk J Surg.* 2025;41(2):154-159

### Corresponding Author

Hilmi Yazıcı

E-mail: hilmiyazici@hotmail.com

ORCID ID: orcid.org/0000-0001-7470-0518

Received: 03.02.2025

Accepted: 05.04.2025

Epub: 13.05.2025

Publication Date: 30.05.2025

DOI: 10.47717/turkjsurg.2025.6760

Available at [www.turkjsurg.com](http://www.turkjsurg.com)



of cancer by comparing different inflammatory markers. Several inflammatory markers, such as neutrophil to lymphocyte ratio, platelet-lymphocyte ratio and systemic inflammation response index, have been defined and used to predict prognosis in various types of cancers (6-9). The hemoglobin, albumin, lymphocyte, platelet score (HALP) index, which was first described by Chen et al. (10), includes a combination of hemoglobin, albumin, lymphocyte, and platelet values. This index indicates nutritional status and systemic inflammation, and provides information about the patient's prognosis. HALP score has been used to determine the prognosis of patients in intensive care units with various types of cancer, such as prostate, breast, and lung cancer (11-16).

In this study, we investigated whether the HALP index can be used as a prognostic marker for CRC.

## MATERIAL and METHODS

A retrospective analysis was conducted on data from patients who underwent CRC surgery between 2017 and 2023 at University of Health Sciences Türkiye, İzmir Bozyaka Training and Research Hospital General Surgery Clinic. Patients who were admitted to our clinic, but whose HALP score could not be calculated due to lack of data and whose disease stage could not be determined, were excluded from the study. Patients' demographic data, radiological images, pathology records, operative notes, and laboratory values were recorded.

Clinical and pathological variables of all included patients were collected from electronic medical records. These included age, gender, comorbid diseases, tumor characteristics (location, degree of differentiation, presence of lymphovascular/perineural invasion, and staging features), presence of mismatch repair mutation, type of surgery performed, total number of lymph nodes removed, number of positive nodes, and information on complications. In addition, preoperative serum albumin, hemoglobin, lymphocyte, and platelet values were collected for all patients to calculate the HALP index. All patients were staged according to the 8<sup>th</sup> edition American Joint Committee on Cancer TNM staging system (17).

HALP index was calculated with the following formula: Hemoglobin level (g/L)  $\times$  albumin level (g/L)  $\times$  lymphocyte count (/L) / platelet count (/L) (10). To investigate the prognostic impact of the HALP score, we determined a cut-off value, calculated by the receiver operating characteristics (ROC) analysis, obtained from the study group. The HALP score cut-off value was calculated as 23. The threshold based on the Youden index (sensitivity + specificity - 1) was chosen to estimate sensitivity and specificity. The cohort of the study was analyzed in two groups according to the determined HALP cut-off.

The primary outcome of this study was to evaluate whether HALP has a prognostic value for CRC.

The secondary outcomes involved evaluating whether HALP predicts early hospital mortality in patients undergoing CRC surgery.

This study was approved by the Ethics Committee of the University of Health Sciences Türkiye, İzmir Bozyaka Training and Research Hospital (no: 2023-200, date: 27.11.2023), and it was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all patients.

## Statistical Analysis

SPSS version 24.0 (SPSS Inc. IBM, Chicago, U.S.) was used for statistical analysis. The continuous data were presented as mean  $\pm$  standard deviation, median, and interquartile range, and categorical data were presented as numbers and frequencies. The proportion or frequency was compared between the two groups using Fisher's exact test or the  $\chi^2$  test, and differences in continuous variables were evaluated using the Student's t-test and the Mann-Whitney U test for non-parametric values. Survival curves were compared using the Kaplan-Meier method and the log-rank test. Cox regression analysis was used for univariate and multivariate overall survival (OS) analysis.

## RESULTS

In our center, 245 patients underwent CRC surgery between January 2017 December 2023. One hundred forty-two patients were excluded from the study because of loss of follow-up, and lack of data. A total of 103 patients were included in the study.

According to ROC analysis, the HALP score cut-off value was calculated as 23. Group 1: HALP score <23. Group 2: HALP score >23 (Figure 1).

The HALP <23 group yielded 60 patients, while the HALP >23 group included 42 patients. Patient demographics such as age, gender, and comorbid disease were similar between the groups. However, the mean hemoglobin level, the mean albumin level, the mean lymphocyte count, and the median platelet counts were significantly different in both groups, as expected (Table 1).

Postoperative outcomes are summarized in Table 2. Only one perioperative mortality case was observed in each group, and the result was not statistically significant. Tumor localization and pathological outcomes were also similar between the two groups.

Univariate and multivariate Cox regression analyses were performed to evaluate prognostic factors for CRC. In the univariate analysis, age, comorbid disease, stage M, and the HALP score were found to be significant in CRC prognosis. However, in

the multivariate analysis, only stage M and the HALP score were poor independent prognostic factors for CRC patients' prognosis (Table 3).

The five-year OS was 68.4% in the HALP <23 group, while the OS was 83.3% in the HALP >23 group. The Kaplan-Meier analysis showed that the HALP <23 group has worse survival outcomes than the HALP >23 group, with a significant result (log-rank: 0.012). Survival curves of the two groups are shown in Figure 2.

DISCUSSION

The HALP index is a criterion that can be used to determine prognosis and survival in cancer patients. It is easy, cheap to

calculate. It is calculated using only four parameters, with all parameters examined for all patients preoperatively. Systemic inflammation plays a crucial role in tumorigenesis. Growing evidence indicates the critical role of lymphocytes, especially in tumor suppression. Moreover, hemoglobin, lymphocytes, and platelet values reflect the synthesis ability of the hematopoietic system. However, its reliability as a prognostic marker in CRC should be carefully interpreted, considering certain limitations. Albumin is a negative acute phase reactant. It varies in inflammatory conditions in the body and in the presence of cancer. Low albumin values are observed in long-term malnutrition. Although albumin is commonly used as a marker of nutritional status and systemic inflammation, its specificity is limited in both acute and chronic inflammatory conditions. This variability may weaken the prognostic significance of the HALP score in CRC patients, where chronic inflammation is a hallmark of disease progression (18). Therefore, the HALP score can be a guide prognosis and survival, not only in malignant but also in benign diseases. Studies on the HALP score are available not only in malignant diseases but also in benign diseases. In a study conducted by Tian et al. (19), they associated low HALP scores with acute ischemic stroke and recurrence within 90 days. In a meta-analysis published by Li et al. (20), high platelet and low lymphocyte values were associated with poor prognosis and OS in cancer patients with an impaired platelet-lymphocyte ratio. A study conducted by Gasparyan et al. (21) found that a high platelet-lymphocyte ratio and a high platelet count in patients are highly predictive of rheumatic disease.

There are limited numbers of studies that investigate the HALP score in relation to CRC prognosis. Different cut-off values for the HALP score have been found in various studies. In the study conducted by Calderillo Ruiz et al. (14) on hispanic-based colon cancer patients, the cut-off value for the HALP score was calculated as 15. Guo et al. (22) reported that HALP score is an important prognostic factor in their study on patients with metastatic prostate cancer. And in this study, the HALP




Figure 1. ROC curve analysis for the HALP score.

Area	Std. error	Asymptotic sig. Lower bound	Asymptotic 95% confidence interval	
			Upper bound	
0.607	0.060	0.108	0.490	0.725

Table 1. Basic characteristics between lower and higher HALP groups			
n=103	HALP <23 (n=60)	HALP >23 (n=42)	p
Age (mean ± SD)	65.1 (±12.8)	63.7 (±13.3)	0.588
Gender (%)			
Male	33 (55%)	30 (71%)	0.091
Female	27 (45%)	12 (29%)	
Comorbid diseases			
Presence	42 (70%)	27 (64%)	0.544
Absence	18 (30%)	15 (36%)	
Pre-operative hemoglobin (g/dL) (mean ± SD)	10.6 (±1.9)	12.6 (±1.9)	<0.001
Pre-operative albumin (g/dL) (mean ± SD)	3.5 (±0.5)	4.1 (±0.6)	<0.001
Pre-operative lymphocyte (mL) (mean ± SD)	1.3 (±0.7)	2 (±0.7)	<0.001
Pre-operative plateletel (cells*10 <sup>9</sup> L) [median (IQR)]	349 (IQR: 165)	256 (IQR: 124)	<0.001

IQR: Interquartile range, HALP: Hemoglobin, albumin, lymphocyte, platelet score, SD: Standard deviation

score cut-off value was determined as 32.4. In the study by Güç et al. (23) on patients with non-small cell lung cancer, the HALP score cut-off value was found to be 23.24. In our study, the cut-off value for the HALP score was found to be 23. In the study conducted by Ekinçi et al. (12) on patients with renal cell carcinoma, the HALP score cut-off value was determined to be 27.7, and an HALP score below 27.7 was associated with poor prognosis. In a study by Zhai et al. (7), the HALP score cut-off value in patients with non-small cell lung cancer was considered 48, and a low HALP score was found to be associated with lower OS. Zhang et al. (24) examined various biomarkers and scores in patients with intrahepatic cholangiocarcinoma. In their study, the HALP score cut-off value was 43.6 and the HALP score was found to be associated with intrahepatic recurrence and lymph

node metastasis (24). Farag et al. (11) reviewed studies including various types of cancer, such as gastric, gastrointestinal, lung, esophageal, pharyngeal, bladder/urothelial, prostate, and gynecological cancers, and mentioned HALP scores. In the analyses, the HALP score cut-off value was between 20-49. Duran et al. (25) in their study on breast cancer patients, reported the HALP score to be 29.01. Although the HALP score alone was not sufficient to predict axillary lymph node positivity, it was found to be associated with advanced or aggressive tumors (25).


Albumin is a negative acute phase reactant. Many different factors affect serum albumin levels, and it has been shown to lack sensitivity and specificity as an indicator of nutritional status. Specifically, acute and chronic inflammatory conditions affect serum albumin levels by altering hepatic protein metabolism and

**Table 2.** Pathological outcomes in both groups

n=103	HALP <23 (n=60)	HALP >23 (n=42)	p
<b>B</b>			
Right colon	17 (28%)	13 (31%)	0.616
Transverse colon	6 (10%)	1 (2%)	
Left colon	9 (15%)	8 (19%)	
Sigmoid colon	10 (17%)	8 (19%)	
Rectum	16 (27%)	9 (22%)	
FAP*/synchronous	2 (3%)	3 (7%)	
<b>Operation</b>			
Right hemicolectomy	23 (38%)	13 (31%)	0.552
Left hemicolectomy	9 (15%)	9 (21%)	
Anterior resection	6 (10%)	5 (13%)	
Low anterior resection	15 (25%)	11 (26%)	
Abdominoperineal resection	5 (9%)	1 (2%)	
Total colectomy	2 (3%)	3 (7%)	
<b>Hospital mortality</b>	1	1	0.797
<b>Stage T</b>			
T1	3 (5%)	2 (5%)	0.637
T2	3 (5%)	4 (10%)	
T3	29 (48%)	23 (55%)	
T4	25 (42%)	13 (30%)	
<b>Stage N</b>			
N0	31 (52%)	20 (48%)	0.670
N1	19 (32%)	12 (29%)	
N2	10 (16%)	10 (23%)	
<b>Stage M</b>			
M0	53 (88%)	38 (90%)	0.731
M1	7 (12%)	4 (10%)	
<b>Pathological stage</b>			
Stage I	5 (8%)	5 (12%)	0.933
Stage II	23 (38%)	16 (38%)	
Stage III	25 (42%)	17 (40%)	
Stage IV	7 (12%)	4 (10%)	
<b>MSI</b>			
High	9 (15%)	6 (14%)	0.920
Low	51 (85%)	36 (86%)	
Harvested lymph nodes [median (IQR)]	21 (20)	20 (16)	0.151
Tumor positive lymph nodes (mean ± SD)	2.3 (±4)	2.4 (±4.4)	0.904
IQR: Interquartile range, HALP: Hemoglobin, albumin, lymphocyte, platelet score, SD: Standard deviation, FAP: Familial adenomatous polyposis, MSI: Microsatellite instability			

Table 3. Univariate and multivariate overall survival analysis for colorectal cancer						
n=124	HR	95% CI	p	HR	95% CI	p
Gender	1.272	0.549-2.950	0.576			
Age	1.061	1.023-1.100	<b>0.001</b>	1.039	0.997-1.084	0.070
Comorbid diseases	7.771	1.827-33.054	<b>0.006</b>	2.473	0.872-7.013	0.089
Tumor localization	0.904	0.675-1.334	0.419			
Operation type	0.978	0.568-1.996	0.841			
Stage T (T1-T2 vs. T3-T4)	5.140	0.489-54.024	0.173			
Stage N (N0 vs. N+)	1.309	0.594-2.885	0.504			
Stage M	3.303	1.190-9.764	<b>0.022</b>	5.287	1.170-23.888	<b>0.030</b>
MSI	1.291	0.386-4.332	0.678			
HALP	0.327	0.130-0.821	<b>0.017</b>	0.314	0.123-0.793	<b>0.014</b>

HR: Hazard ratio, CI: Confidence interval, MSI: Microsatellite instability, HALP: Hemoglobin, albumin, lymphocyte, platelet score



**Figure 2.** Overall survival in HALP <23 and HALP >23 groups. (Log-rank: 0.012).

HALP: Hemoglobin, albumin, lymphocyte, platelet score

inducing capillary leakage. This being the case, serum albumin is no longer considered a reliable nutritional marker in inflammatory states but rather a marker for disease severity (26). It is seen often in hospitalized patients and is associated with a poor clinical course (27). There are many factors that affect serum albumin levels. Although it provides information about nutritional status, its specificity is low (28). The real reason for low serum albumin levels has been a subject of debate for a long time. It is known that malnutrition is related to hypoalbuminemia (29). Albumin levels have also been found to be low in acute and chronic inflammation. Therefore, it seems logical to include the albumin multiplier in the calculation of the HALP score because CRC patients are associated with both chronic inflammation and malnutrition.

Hemoglobin is responsible for carrying oxygen in the blood. It is found in red blood cells, and one of its building blocks is

iron. In colorectal cancers, blood may be present in the stool due to spontaneous bleeding of the cancer. Low hemoglobin may be associated with colorectal cancers in older ages (30). In addition, anemia may be seen in conditions such as chronic inflammation (31). There is a hemoglobin multiplier in the HALP score calculation, so a low HALP score may be associated with a low hemoglobin value.

### Study Limitations

This study has some limitations as well. First, its retrospective design might lead to some selection biases. Second, the relatively small number of patients might affect the strength of the statistical analysis. Finally, this study was conducted in a single center; hence, this may affect the generalizability of the results.

### CONCLUSION

HALP score is an easy and inexpensive method to calculate. In CRC cases, poor HALP score is associated with low OS. Therefore, using the HALP score in CRC cases can provide information about OS.

### Ethics

**Ethics Committee Approval:** This study was approved by the Ethics Committee of the University of Health Sciences Türkiye, İzmir Bozyaka Training and Research Hospital (no: 2023-200, date: 27.11.2023), and it was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

**Informed Consent:** Informed consent was obtained from all patients.

### Footnotes

#### Author Contributions

Concept - Ö.Ç., H.Y., A.C.Y., Y.Ç., B., S.T., E.O., A.M.Ö., M.Y.; Design - Ö.Ç., H.Y., A.C.Y., Y.Ç., B., S.T., E.O., A.M.Ö., M.Y.; Data Collection or Processing - Ö.Ç., Y.Ç., B., A.C.Y.; Writing - H.Y., S.T., E.O.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## REFERENCES

1. Tatar M, Tatar F. Colorectal cancer in Turkey: Current situation and challenges for the future. *Eur J Health Econ*. 2010;99-105.
2. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. *CA Cancer J Clin*. 2023;73:233-254.
3. Karabulut S, Karabulut M, Taştekin D. What's new in metastatic colon cancer treatment? *J Ist Faculty Med*. 2021;84:425-429.
4. Arslan NC, Sokmen S, Canda AE, Terzi C, Sarioglu S. The prognostic impact of the log odds of positive lymph nodes in colon cancer. *Colorectal Dis*. 2014;16:386-392.
5. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;860-867.
6. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. *Ann Oncol*. 2015;26:750-755.
7. Zhai B, Chen J, Wu J, Yang L, Guo X, Shao J, et al. Predictive value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and lymphocyte-to-monocyte ratio (LMR) in patients with non-small cell lung cancer after radical lung cancer surgery. *Ann Transl Med*. 2021;9:976.
8. Yazici H, Yegen SC. Is systemic inflammatory response index (SIRI) a reliable tool for prognosis of gastric cancer patients without neoadjuvant therapy? *Cureus*. 2023;15:36597.
9. Yazici H, Eren Kayaci A, Sevindi HI, Attaallah W. Should we consider systemic inflammatory response index (SIRI) as a new diagnostic marker for rectal cancer? *Discov Oncol*. 2024;15:44.
10. Chen XL, Xue L, Wang W, Chen HN, Zhang WH, Liu K, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. *Oncotarget*. 2015;6:41370-41382.
11. Farag CM, Antar R, Akosman S, Ng M, Whalen MJ. What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP's prognostic ability in different cancer types. *Oncotarget*. 2023;14:153-172.
12. Ekinci F, Balcik OY, Oktay E, Erdogan AP. HALP score as a new prognostic index in metastatic renal cell cancer. *J Coll Physicians Surg Pak*. 2022;32:313-318.
13. Kaya C, Caliskan S, Sungur M, Aydın C. HALP score and albumin levels in men with prostate cancer and benign prostate hyperplasia. *Int J Clin Pract*. 2021;75:13766.
14. Calderillo Ruiz G, Lopez Basave H, Vazquez Renteria RS, Castillo Morales A, Guijosa A, Castillo Morales C, et al. The prognostic significance of HALP index for colon cancer patients in a hispanic-based population. *J Oncol*. 2022;2022:4324635.
15. Akbas A, Koyuncu S, Hacim NA, Dasiran MF, Kasap ZA, Okan I. Can HALP (hemoglobin, albumin, lymphocytes, and platelets) score differentiate between malignant and benign causes of acute mechanical intestinal obstruction? *Cancer Biother Radiopharm*. 2022;37:199-204.
16. Keten T, Ozercan AY, Eroglu U, Basboga S, Tatlici K, Senel C, et al. Can HALP score, a new prognostic tool, take the place of traditional scoring systems in Fournier's gangrene? *Int Urol Nephrol*. 2023;55:2389-2395.
17. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J Clin*. 2017;67:93-99.
18. Kaya T, Ulaş SB, Nalbant A, Yıldırım İ, İşsever K, Karacaer C, et al. C-reactive protein/albumin ratio as a novel predictor for nutritional status of geriatric patients. *Brain Behav*. 2024;14:70017.
19. Tian M, Li Y, Wang X, Tian X, Pei LL, Wang X, et al. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is associated with poor outcome of acute ischemic stroke. *Front Neurol*. 2021;11:610318.
20. Li B, Zhou P, Liu Y, Wei H, Yang X, Chen T, et al. Platelet-to-lymphocyte ratio in advanced cancer: Review and meta-analysis. *Clin Chim Acta*. 2018;483:48-56.
21. Gasparyan AY, Ayyazyan L, Mukanova U, Yessirkepov M, Kitaz GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. *Ann Lab Med*. 2019;39:345-357.
22. Guo Y, Shi D, Zhang J, Mao S, Wang L, Zhang W, et al. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a novel significant prognostic factor for patients with metastatic prostate cancer undergoing cytoreductive radical prostatectomy. *J Cancer*. 2019;10:81-91.
23. Güç ZG, Alacacioğlu A, Kalender ME, Oflazoğlu U, Ünal S, Yıldız Y, et al. HALP score and GNRI: Simple and easily accessible indexes for predicting prognosis in advanced stage NSCLC patients. The İzmir oncology group (IZOG) study. *Front Nutr*. 2022;9:905292.
24. Zhang D, Zeng H, Pan Y, Zhao Y, Wang X, Chen J, et al. Liver tumor markers, HALP score, and NLR: simple, cost-effective, easily accessible indexes for predicting prognosis in ICC patients after surgery. *J Pers Med*. 2022;12:2041.
25. Duran A, Pulat H, Cay F, Topal U. Importance of HALP score in breast cancer and its diagnostic value in predicting axillary lymph node status. *J Coll Physicians Surg Pak*. 2022;32:734-739.
26. Eckart A, Struja T, Kutz A, Baumgartner A, Baumgartner T, Zurluh S, et al. Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a prospective study. *Am J Med*. 2020;133:713-722.
27. Truong A, Hanna MH, Moghadamyeghaneh Z, Stamos MJ. Implications of preoperative hypoalbuminemia in colorectal surgery. *World J Gastrointest Surg*. 2016;8:353.
28. Levitt DG, Levitt MD. Human serum albumin homeostasis: A new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. *Int J Gen Med*. 2016;9:229-255.
29. Don BR, Kaysen G. Poor nutritional status and inflammation: Serum albumin: Relationship to inflammation and nutrition. *Seminars in Dialysis*. 2004;17:432-437.
30. Schneider C, Bodmer M, Jick SS, Meier CR. Colorectal cancer and markers of anemia. *Eur J Cancer Prev*. 2018;27:530-538.
31. Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and inflammation driven pathophysiology of iron homeostasis—mechanistic insights into anemia of inflammation and its treatment. *Nutrients*. 2021;13:3732.